Emerging drugs for Epstein-Barr virus associated-diseases

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Epstein-Barr virus (EBV) is the first identified oncogenic virus.
• EBV causes lymphomas, carcinomas, and autoimmune diseases, leading to an estimated 200,000 deaths annually.
• EBV establishes lifelong latency post-infection, with reactivation to the lytic phase inducible by various agents.

Purpose of the Study:

• To review recent advancements in small organic compounds targeting EBV-associated diseases.
• To highlight emerging therapeutic strategies focusing on EBV-specific targets.

Main Methods:

• Literature review of studies on small organic molecules and biologics for EBV reactivation.
• Analysis of research on treatments targeting Epstein-Barr Nuclear Antigen 1 (EBNA1).

Main Results:

• Small organic compounds demonstrate efficacy against EBV-associated diseases.
• Emerging treatments targeting EBNA1 using small organic molecules show promising results.
• These targeted therapies are effective against several EBV-related malignancies.

Conclusions:

• Small organic molecules represent a viable therapeutic avenue for EBV-driven diseases.
• Targeting EBNA1 is a promising strategy for developing novel anti-EBV therapies.
• Further research into these compounds could lead to improved treatments for EBV-related cancers and autoimmune conditions.